Organ Transplantation Stocks
Advanced biomedical engineering and diagnostic platforms drive this sector by addressing the critical shortage of viable organs and the high risk of post-operative rejection. Revenue models rely on high-margin hardware for organ preservation, genomic testing for graft monitoring, and long-term immunosuppressant therapies.
As of Oct 23, 2026, Organ Transplantation has 8 US-listed companies worth $89.8B combined. The median member moved +2.7% over the past week; UTHR led at +10.2% and IMDX trailed at -6.0%.
Companies in Organ Transplantation
- NTRA – Natera Inc, $57.9B
- UTHR – United Therapeutics Corporation, $25.1B
- CDNA – CareDx Inc, $3.6B
- TMDX – TransMedics Group Inc, $2.5B
- SRTA – Strata Critical Medical, Inc., $418M
- ELDN – Eledon Pharmaceuticals Inc, $190M
- HUMA – Humacyte Inc, $119M
- IMDX – Insight Molecular Diagnostics Inc., $107M